Study of chidamide and azacitidine for AML patients with MRD after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AML (a type of blood cancer, not including M3 subtype) and have had a donor stem cell transplant (allo-HSCT).
- After transplant, tests show you still have tiny amounts of leukemia cells (called MRD positive).
- You are 18 years or older.
- You are able to take care of yourself most of the day (ECOG score 3 or less).
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the combination of azacitidine and venetoclax works for people with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The trial measures a microscopic sign of cancer called measurable residual disease (MRD) to see how the treatment affects survival.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
This trial tests a combination of drugs for people with AML who, after initial treatment, have very low levels of leukemia still present (called measurable residual disease or MRD). The goal is to wipe out these remaining cells and reduce the chance of the cancer coming back.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.